Journal article
Oncolytic viruses: a step into cancer immunotherapy
Abstract
Oncolytic virotherapy is currently under investigation in phase I–III clinical trials for approval as a new cancer treatment. Oncolytic viruses (OVs) selectively infect, replicate in, and kill tumor cells. For a long time, the therapeutic efficacy was thought to depend on the direct viral oncolysis (virocentric view). The host immune system was considered as a brake that impaired virus delivery and spread. Attention was paid primarily to …
Authors
Pol JG; Rességuier J; Lichty BD
Journal
Virus Adaptation and Treatment, Vol. 4, No. 0, pp. 1–21
Publisher
Taylor & Francis
Publication Date
December 28, 2011
DOI
10.2147/vaat.s12980
ISSN
1179-1624